Time course of rapid C-reactive protein reduction by pravastatin in patients with stable angina

Angiology

Volumn 57, Issue 1, 2006, Pages 1-7

  Li, Jian Jun ^a,b   Fang, Chun Hong ^a   Qian, Hai Yan ^a   Hu, Wen Lan ^a  

^a FUWAI HOSPITAL   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; LIPID; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; BIOLOGICAL MARKER; HYPOCHOLESTEROLEMIC AGENT; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MALE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STABLE ANGINA PECTORIS; TIME; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; BLOOD; FOLLOW UP; HOSPITALIZATION; METABOLISM; MIDDLE AGED; PHOTOMETRY; RADIOGRAPHY; TREATMENT OUTCOME;

ANGINA PECTORIS; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL; CORONARY ANGIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PRAVASTATIN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 33645311281     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970605700101     Document Type: Article

References (29)

1. Maseri A: Inflammation, atherosclerosis, and ischemic events: Exploring the hidden side of the moon. N Engl J Med 336:1014-1016, 1997.
2. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 340:115-126, 1993.
3. Libby P, Ridker PM: Novel inflammatory markers of coronary risk: Theory versus practice. Circulation 100:1148-1150, 1999.
4. Plenge JK, Hernandez TL, Weil KM, et al: Simvastatin lowers C-reactive protein within 14 days: An effect independent of low-density lipoprotein cholesterol reduction. Circulation 106:1447-1452, 2002.
5. Li J-J, Chen M-Z, Chen-X, et al: Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia. Clin Cardiol 26:472-476, 2003.
6. Li J-J, Chen X-J: Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. Coron Artery Dis 14:329-334, 2003.
7. Jackson G: The role of statins in acute coronary syndromes: Managing the unmet need. Int J Clin Pract 54:445-449, 2000.
8. Szucs TD: Pharmaco-economic aspects of lipid-lowering therapy: Is it worth the price? Eur Heart J 19(suppl M):M22-M28, 1998.
9. Fairhurst K, Huby G: From trial data to practical knowledge: Qualitative study of how general practitioners have accessed and used evidence about statin drugs in their management of hypercholesterolaemia. BMJ 317:1130-1134, 1998.
10. Azar RR, Waters DD, Lebanon B: PRINCE's prospects: Statin, inflammation, and coronary risk. Am Heart J 141:881-883, 2001.
11. Treasure CB, Klein JL, Weintraub WS, et al: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332:481-487, 1995.
12. Schrott HG, Knapp H, Davila M, et al: Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: A randomized, placebo-controlled study. Am Heart J 140:249-252, 2000.
13. Dupuis J, Tardif J, Theroux P, et al: Cholesterol reduction rapidly improves endothelial function after acute coronary syndrome. J Am Coll Cardiol 31:891-896, 1998.
14. Arntz HR, Wunderlich W, Schnitzer L: The decisive importance of cholesterol lowering therapy for coronary lesion and clinical course immediately after an acute coronary event: Short and long-term results of a controlled study. Circulation 98(suppl 1):1-45, 1998.
15. Ridker PM, Rifai N, Pfeffer MA, et al, for the cholesterol and recurrent Events (CARE) investigators: Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100:230-235, 1999.
16. Miller M, Dolinor C, Cromwell W, et al: Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia. Am J Cardiol 87:232-223, 2001.
17. Ridker PM, Rifai N, Lowenthal SP: Rapid reduction in C-reactive with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 103:1191-1193, 2001.
18. Ridker PM, Rifai N, Pfeffer MA, et al: Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100:230-235, 1999.
19. Li J-J, Fang C-H: C-reactive protein is not only a marker but also direct cause of cardiovascular disease. Med Hypotheses 62:499-506, 2004.
20. Meier-Ewert HK, Ridker PM, Rifai N, et al: Absence of diurnal variation of C-reactive protein levels in healthy human subjects. Clin Chem 47:444-450, 2001.
21. Ockene IS, Matthews CE, Rifai N, et al: Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 47:444-450, 2001.
22. Li J-J, Jiang H, Huang C-X, et al: Elevated levels of plasma C-reactive protein in patients with unstable angina: Its relations with coronary stenosis and lipid profile. Angiology 53:265-272, 2002.
23. Ridker PM, Cushman M, Stampfer MJ, et al: Inflammation, aspirin and risks of cardiovascular disease in apparently healthy men. N Engl J Med 336:973-979, 1997.
24. Li J-J, Huang C-X, Jiang H, et al: Circadian Variation in ischemic threshold in patients with stable angina: Relation to plasma endothelin-1. Angiology 53:409-413, 2002.
25. Li J-J, Huang C-X, Jiang H, et al: Ischemic preconditioning detected by treadmill exercise tests in patients with stable angina. Angiology 54:45-50, 2003.
26. Gensini GC: A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 51:606, 1983.
27. Schrott HG, Bittner V, Vittinghoff E, et al: Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease: The Heart and Estrogestin Replacement Study (HERS). JAMA 277:1281-1286, 1997.
28. Knapp HH, Schrott H, Ma P, et al: Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 110:352-360, 2001.
29. Reed RG, Fong SY, Pearson TA, et al: Role of a central laboratory in implementing National Cholesterol Education Panel guidelines in rural practices: Model system for managed care. Clin Chem 41:271-274, 1995.